🇺🇸 FDA

Intelligence Platform

Patents

Browse 1,022 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11440883

Heterocyclic compound and use thereof

Takeda Pharmaceutical Company Limited · Granted Tue Sep 13 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11434304

Anti-CD38 antibodies

Takeda Pharmaceutical Company Limited · Granted Tue Sep 06 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11433029

Formulation of an antibody and use thereof

Takeda Pharmaceutical Company Limited · Granted Tue Sep 06 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11427605

Crystalline forms of 5-chloro-N4-[-2-(dimethylphosphoryl) phenyl]-N2-{2-methoxy-4-[4-(4-me

Takeda Pharmaceutical Company Limited · Granted Tue Aug 30 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 25 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11426397

Piperidinyl- and piperazinyl-substituted heteroaromatic carboxamides as modulators of GPR6

Takeda Pharmaceutical Company Limited · Granted Tue Aug 30 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 25 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11414496

Anti-CD38 binding domains

Takeda Pharmaceutical Company Limited · Granted Tue Aug 16 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 11 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11406710

Constrained conditionally activated binding proteins

Takeda Pharmaceutical Company Limited · Granted Tue Aug 09 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 04 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11407748

Substituted pyrido[1,2-a]pyrimidines and pyrazino[1,2-a]pyrimidines for enhancing AMPA rec

Takeda Pharmaceutical Company Limited · Granted Tue Aug 09 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 04 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11407984

Methods for purification of arysulfatase A

Takeda Pharmaceutical Company Limited · Granted Tue Aug 09 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 04 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11401346

Nucleic acids encoding plasma kallikrein binding proteins

Takeda Pharmaceutical Company Limited · Granted Tue Aug 02 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11390634

Fused heterocyclic compound

Takeda Pharmaceutical Company Limited · Granted Tue Jul 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11389533

Method of treating inflammatory bowel disease

Takeda Pharmaceutical Company Limited · Granted Tue Jul 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11390687

Bispecific antibodies against plasma kallikrein and Factor XII

Takeda Pharmaceutical Company Limited · Granted Tue Jul 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11372002

Assays for determining plasma kallikrein system biomarkers

Takeda Pharmaceutical Company Limited · Granted Tue Jun 28 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 23 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11370803

Heteroaryl plasma kallikrein inhibitors

Takeda Pharmaceutical Company Limited · Granted Tue Jun 28 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 23 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11357832

Treatment of cognitive impairment of hunter syndrome by intrathecal delivery of iduronate-

Takeda Pharmaceutical Company Limited · Granted Tue Jun 14 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 09 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11352356

Inhibitors of plasma kallikrein and uses thereof

Takeda Pharmaceutical Company Limited · Granted Tue Jun 07 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 02 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11344610

Prevention and reduction of blood loss

Takeda Pharmaceutical Company Limited · Granted Tue May 31 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 26 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11340237

Metabolite biomarkers for diseases associated with the contact activation system

Takeda Pharmaceutical Company Limited · Granted Tue May 24 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 19 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11319286

Heterocyclic compound and application thereof

Takeda Pharmaceutical Company Limited · Granted Tue May 03 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11299553

Anti-plasma kallikrein antibodies

Takeda Pharmaceutical Company Limited · Granted Tue Apr 12 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11299533

Purification of factor VIII subspecies

Takeda Pharmaceutical Company Limited · Granted Tue Apr 12 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11292766

Substituted piperidine compound and use thereof

Takeda Pharmaceutical Company Limited · Granted Tue Apr 05 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 31 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11285139

Treatment of CNS conditions

Takeda Pharmaceutical Company Limited · Granted Tue Mar 29 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted